11 Best Performing Stocks in the Last 12 Months

2. Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

1-Year Share Performance: 674.61%

Number of Hedge Fund Holders: 29

On January 16, 2026, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) announced that it has made a strategic amendment to its Exclusive Option and License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd. Through this move, the company converted its prior non-exclusive, royalty-free license to certain patents into an exclusive, sublicensable, royalty-bearing, perpetual worldwide license, though not including the Hansoh Territory. The license pertains to therapeutic products containing TERN-701 as the sole active ingredient. The development helps the company strengthen its commercialization rights outside China, Taiwan, Hong Kong, and Macau.

Under the amendment, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) will be liable to pay Hansoh a one-time upfront license fee of $1.0 million and tiered royalties of 0.75%-1.25% on annual net sales of 701 Products. However, these liabilities will be subject to reductions where applicable.

Meanwhile, in the previous month, Citizens revisited Terns Pharmaceuticals, Inc. (NASDAQ:TERN), raising its price target from $35 to $57, while reiterating an ‘Outperform’ rating. The bullish tone reflected the interim Phase 1 CARDINAL ASH update that featured TERN-701’s best-in-class profile, high deep molecular response rate in 1L, and strong activity post-asciminib and ponatinib in 2L.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) focuses on developing small-molecule and combination therapies for NASH, oncology, and chronic liver disease. Its clinical-stage programs span FXR, VAP-1, THR-β, and GLP-1 targets.